Thursday, September 17, 2009

The truth about AdvaCAL vs Algaecal.

A competitor to AdvaCAL calcium, called Algaecal, claims to increase bone density like AdvaCAL. The single Algaecal study cannot support any prolonged bone building claim for the following reasons:

The Algaecal trial consisted of patients taking 2400mg!! of algaecal calcium daily, taking 2 independently bone builders: ( vitamin D & strontium (which was a separate pill taken at a different time)) AND partaking in a weight training/walking program! The AdvaCAL studies only involved only 900mg AAACa calcium. Nothing else

Algaecal was not tested alone, the standard method for most calcium supplement trials. Algaecal study participants also took strontium, a mineral independently shown to increase bone density. Additionally, Algaecal participants were encouraged to exercise and make diet changes, changes that likely could increase bone mineral density. The AdvaCAL clinical studies only tested AdvaCAL calcium; no other ingredients or lifestyle changes were involved

The Algaecal study only measured bone density for 6 months. The AdvaCAL studies demonstrated steady bone density increases up to 3 years.

The Algaecal study had no placebo group, involved patients 18- 85 and employed unconventional extrapolation of data.

The AdvaCAL studies were double-blind, placebo controlled and studied postmenopausal or elderly subjects. The AdvaCAL studies were published in scientific journals and subject to appropriate scientific scrutiny.

Don't be fooled...

Thursday, September 10, 2009

“Total Victory” Ruling for LaneLabs over FTC

August 13, 2009

Newark, NJ -- A U.S. District Court Judge ruled in favor of LaneLabs – USA, Inc. denying a contempt motion filed by the Federal Trade Commission (FTC) on advertising claims for two popular LaneLabs supplements. Judge Dennis M. Cavanaugh wrote that LaneLabs “clearly offered support and substantiation for claims” on AdvaCAL, a premium calcium supplement and Fertil Male. Jack Wenik, the Sills Cummis & Gross attorney representing LaneLabs, hailed the ruling a “Total Victory.”

The FTC filed suit on January 11, 2007 charging that LaneLabs had violated an earlier consent decree by making claims for AdvaCAL and Fertil Male without competent and reliable evidence. The FTC and LaneLabs presented competing fact and expert testimony during a five-day hearing before Judge Cavanaugh in April, 2009. On August 11, 2009 the judge ruled in favor of LaneLabs on every contested point. He found the testimony of Andrew Lane, president of LaneLabs “forthcoming and credible” and was “more impressed” by the testimony of the LaneLabs experts.

According to Andrew Lane, the FTC was overmatched by the science. Twenty peer reviewed, published scientific papers supported the efficacy of AdvaCAL and Fertil Male. As a result, the judge wrote the FTC presented a “nuanced case.” LaneLabs “provided credible medical testimony that the products in question are good products and could have the results advertised…"

“This was not a split decision victory for LaneLabs; it was a clean sweep” Lane commented . “I am heartened that a Federal Judge with no vested interest – other than right and wrong – agreed with us. AdvaCAL calcium simply works better; it’s an important product the FTC wanted to quash and now cannot. This ruling is a big win for LaneLabs, other scientifically-advanced natural companies and the millions who trust specialty supplements .”

AdvaCAL® is a patented Japanese calcium supplement advertised as the #1 bone building calcium. Clinical studies show that AdvaCAL calcium can actually increase bone density in postmenopausal and elderly women. Fertil Male is a proprietary herbal supplement that supports healthy sperm activity. Both products are sold by health food stores, nutrition websites and from dispensing health professionals.

Founded in 1994, LaneLabs, (Waldwick, NJ) specializes in natural compound research and marketing. Many LaneLabs supplements and topicals are patented and backed by clinical research showing unique health benefits. For more information:, call 1-800-526-3005.